GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro have taken the world by storm. Initially approved for type 2 diabetes, they quickly became household names for their impressive weight-loss effects. Backed by celebrity endorsements and millions of success stories, these medications promised not just slimmer bodies, but longer, healthier lives.
But a growing number of adverse event...
